Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | HTR2B | P41595 | 5/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662706 | 0.93 | HTR2C (0.58) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23723381 | 0.88 | HTR2A (0.65) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL29361303 | 0.80 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23723408 | 0.80 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL23723384 | 0.75 | HTR2A (0.48) | HTR2AHTR6 | |
| SCHEMBL29938186 | 0.75 | HTR2A (0.48) | HTR2AHTR6 | |
| SCHEMBL23723386 | 0.75 | HTR2A (0.48) | HTR2AHTR6 | |
| SCHEMBL23723275 | 0.75 | HTR2A (0.44) | HTR2CHTR2AHTR2BHTR6HDAC1 | |
| SCHEMBL23723320 | 0.74 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR6HTR1A | |
| SCHEMBL29936591 | 0.74 | HTR2C (0.70) | HTR2CHTR2AHTR2BHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116901-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA, INC. (CA) | 2025-12-25 | — | — | US | disclosed |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20240317782-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| CN-115974757-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-03-07 | — | — | US | disclosed |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-02-28 | — | — | US | disclosed |
| EP-4100391-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397810-A | Silodosin derivatives as serotonergic hallucinogens for the treatment of CNS disorders | 明德赛特制药公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-10-13 | — | — | US | disclosed |
| US-20220289774-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-09-15 | — | — | US | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| WO-2021155470-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324889-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | HTR2C 5/4885HTR2A 8/4885HTR2B 16/4885 |
| US-20230118872-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-12378266-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-12054505-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20250388611-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR6, CNR1, HTR1D | HTR2C 5/4885HTR2A 16/4885HTR2B 28/4885 |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20240317782-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
| US-20260116901-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR6, CNR1, HTR2C | HTR2C 3/4885HTR2A 13/4885HTR2B 19/4885 |
| US-20220289774-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | HTR2C 7/4885HTR2A 4/4885HTR2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.